MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,090.00
+25.00 (0.62%)
Aug 14, 2025, 2:38 PM KST
-43.19%
Market Cap 140.87B
Revenue (ttm) 429.94M
Net Income (ttm) -14.22B
Shares Out 34.28M
EPS (ttm) -422.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,406
Average Volume 283,896
Open 4,070.00
Previous Close 4,065.00
Day's Range 4,025.00 - 4,130.00
52-Week Range 2,750.00 - 7,850.00
Beta 0.64
RSI 50.09
Earnings Date Aug 8, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Employees 61
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.